中国P站

Mucosal immunopathology; Inflammation; Autoimmune diseases; Gut immunity; Respiratory immunity; Microbiota; Autoimmunity

Introduction

Mucosal tissues, found in the gastrointestinal, respiratory, and urogenital tracts, play a critical role in protecting the body from pathogens, allergens, and toxins. These tissues are lined with specialized immune systems designed to maintain homeostasis while defending against harmful invaders. However, when immune regulation is disrupted, chronic inflammation can result, contributing to the development of autoimmune diseases [1]. The mucosal immune system is composed of various components, including mucosal-associated lymphoid tissues (MALT), epithelial cells, and secretory immunoglobulin A (IgA). These elements work together to monitor and respond to environmental factors while maintaining tolerance to harmless antigens. In autoimmune diseases, an inappropriate immune response against self-antigens at mucosal sites leads to tissue damage and disease progression [2]. Inflammatory bowel disease (IBD), asthma, and systemic lupus erythematosus (SLE) are examples of autoimmune diseases where mucosal inflammation plays a significant role. In IBD, immune dysregulation within the gut leads to chronic inflammation, while in asthma, aberrant immune responses in the airways cause airway inflammation and hypersensitivity. SLE, a systemic autoimmune disorder, involves the activation of autoantibodies against self-antigens, affecting multiple organs, including the mucosal surfaces [3]. Microbiota, genetic factors, and environmental triggers also contribute to the onset and progression of autoimmune diseases by altering immune responses in mucosal tissues. The interaction between the host immune system and the microbiome is particularly important in regulating inflammation and immune tolerance. Recent research highlights the role of dysbiosis in promoting mucosal inflammation and exacerbating autoimmune diseases [4]. This review aims to explore the immunopathological mechanisms involved in mucosal inflammation and their link to autoimmune diseases, highlighting potential therapeutic targets and strategies to manage these conditions.

Methods

Studies were selected based on their relevance to the immunological mechanisms in mucosal tissues, including inflammatory pathways, immune dysregulation, and the role of microbiota in autoimmune disease pathogenesis. Both clinical studies and experimental models were considered, with a focus on research that addressed the molecular and cellular processes underlying mucosal inflammation in diseases such as IBD, asthma, and SLE [5]. In addition, articles that discussed therapeutic interventions targeting mucosal immune responses or microbiome modulation were included. The selected studies were organized into categories such as immune regulation, microbiota-immune interactions, and inflammatory mediators. This allowed for an in-depth understanding of the immunopathology of mucosal tissues and its impact on autoimmune diseases.

Results

The review revealed several key inflammatory mechanisms contributing to autoimmune diseases in mucosal tissues. In IBD, increased production of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, disrupts the integrity of the intestinal epithelial barrier, leading to chronic inflammation and tissue damage. Dysbiosis, or the imbalance of gut microbiota, further exacerbates the inflammatory response, promoting immune activation and persistent inflammation. In asthma, the mucosal immune system in the airways shows heightened sensitivity to environmental allergens, resulting in the activation of Th2 cells and the release of cytokines such as IL-4, IL-5, and IL-13. These cytokines drive eosinophilic inflammation, airway remodeling, and bronchial hyperreactivity. Additionally, a disrupted airway microbiome has been implicated in altering immune responses and exacerbating asthma symptoms. Systemic lupus erythematosus (SLE) is characterized by the production of autoantibodies that target self-antigens, including those expressed in mucosal tissues. Chronic inflammation within these tissues contributes to the systemic nature of SLE, leading to multi-organ involvement and symptoms such as mucosal ulcers. The immune dysregulation seen in SLE is influenced by genetic predisposition, environmental factors, and alterations in mucosal immune responses. Microbial dysbiosis in all three diseases was found to play a significant role in immune modulation, with imbalances leading to either excessive inflammation or impaired immune tolerance.

Discussion

Mucosal tissues are a critical site for the initiation and regulation of immune responses, and their dysregulation can lead to the development of autoimmune diseases. In IBD, the inflammatory response involves a complex interplay between host immune cells and microbial components, leading to persistent gut inflammation. Disruption of the intestinal barrier and alterations in the gut microbiota promote a vicious cycle of inflammation [6]. Similarly, in asthma, the mucosal immune system in the airways responds inappropriately to environmental stimuli, resulting in chronic inflammation and airway obstruction. The balance between Th1 and Th2 immune responses plays a pivotal role in this process, and Th2-mediated inflammation is responsible for much of the airway hypersensitivity seen in asthma [7]. SLE exemplifies the systemic nature of autoimmune diseases, where immune responses at mucosal surfaces contribute to systemic inflammation and multi-organ damage. The production of autoantibodies, particularly those targeting nucleic acids, leads to the formation of immune complexes that deposit in tissues and trigger inflammatory responses. The influence of microbiota in autoimmune diseases highlights the importance of microbial homeostasis in regulating mucosal immunity. Microbial dysbiosis can exacerbate inflammatory processes and alter immune responses, suggesting that restoring a healthy microbiome may be an effective therapeutic strategy [8]. Understanding the molecular pathways involved in mucosal immune regulation provides opportunities for targeted treatments that modulate immune responses and restore balance.

Conclusion

The immunopathology of mucosal tissues is central to the pathogenesis of autoimmune diseases, where chronic inflammation and immune dysregulation at these sites contribute to tissue damage and disease progression. Inflammatory mechanisms involving cytokines, immune cells, and microbial dysbiosis play pivotal roles in diseases like IBD, asthma, and SLE. Recent advances in understanding mucosal immune regulation and its interaction with the microbiota offer new therapeutic avenues for treating autoimmune diseases. Strategies such as restoring microbial balance, modulating immune responses, and targeting specific inflammatory pathways hold promise in reducing disease burden and improving patient outcomes. Further research into mucosal immunopathology and the development of targeted therapies could provide significant advances in autoimmune disease management.

References

1. Latz E, Xiao TS, Stutz A (2013) . Nat Rev Immunol 13: 397-411.

   , ,

2. Miao EA, Rajan JV, Aderem A (2011) . Immunol Rev 243: 206-214.

   , ,

3. Sansonetti PJ, Phalipon A, Arondel J, Thirumalai K, Banerjee S, et al. (2000) . Immunity 12: 581-590.

   , ,

4. Vajjhala PR, Mirams RE, Hill JM (2012) . J Biol Chem 287: 41732-41743.

   , ,

5. Proell M, Gerlic M, Mace PD, Reed JC, Riedl SJ, et al. (2013) . Biochem J 449: 613-621.

   , ,

6. Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, et al. (2008) . Immunity 28: 285-287.

   , ,

7. Fernandes AT, Wu J, Yu JW, Datta P, Miller B, et al. (2007) . Cell Death Differ 14: 1590-1604.

   , ,

8. Zaba LC, Farinas SM, Duculan FJ, Nograles KE, Yassky GE, et al. (2009) . J Allergy Clin Immunol 124: 1022-1030.

   , ,